Theravance Biopharma Inc
NASDAQ:TBPH

Watchlist Manager
Theravance Biopharma Inc Logo
Theravance Biopharma Inc
NASDAQ:TBPH
Watchlist
Price: 9.875 USD 0.87%
Market Cap: 485.6m USD
Have any thoughts about
Theravance Biopharma Inc?
Write Note

Intrinsic Value

The intrinsic value of one TBPH stock under the Base Case scenario is 7.174 USD. Compared to the current market price of 9.875 USD, Theravance Biopharma Inc is Overvalued by 27%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

TBPH Intrinsic Value
7.174 USD
Overvaluation 27%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Theravance Biopharma Inc

Intrinsic Value History
Dive into the past to invest in the future

Uncover deeper insights with the Valuation History. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start now and learn if your stock is truly undervalued or overvalued!

Start Valuation
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
TBPH
Valuation History
HIDDEN
Show
Valuation History Unavailable

Historical valuation for TBPH cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
How do you feel about TBPH?
Bearish
Neutral
Bullish

Fundamental Analysis

9.875 USD
+0.87%
+0.87%
Benchmark
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Theravance Biopharma Inc
KY
Pharmaceuticals
Market Cap
485.6m USD
IPO
May 16, 2014
Employees
158
Cayman Islands
Market Cap
485.6m USD
Industry
Pharmaceuticals
IPO
May 16, 2014
Company Overview
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
AI Assistant
AI Assistant
Ask me anything about Theravance Biopharma Inc

Provide an overview of the primary business activities
of Theravance Biopharma Inc.

What unique competitive advantages
does Theravance Biopharma Inc hold over its rivals?

What risks and challenges
does Theravance Biopharma Inc face in the near future?

Has there been any significant insider trading activity
in Theravance Biopharma Inc recently?

Summarize the latest earnings call
of Theravance Biopharma Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Theravance Biopharma Inc.

Provide P/S
for Theravance Biopharma Inc.

Provide P/E
for Theravance Biopharma Inc.

Provide P/OCF
for Theravance Biopharma Inc.

Provide P/FCFE
for Theravance Biopharma Inc.

Provide P/B
for Theravance Biopharma Inc.

Provide EV/S
for Theravance Biopharma Inc.

Provide EV/GP
for Theravance Biopharma Inc.

Provide EV/EBITDA
for Theravance Biopharma Inc.

Provide EV/EBIT
for Theravance Biopharma Inc.

Provide EV/OCF
for Theravance Biopharma Inc.

Provide EV/FCFF
for Theravance Biopharma Inc.

Provide EV/IC
for Theravance Biopharma Inc.

Show me price targets
for Theravance Biopharma Inc made by professional analysts.

What are the Revenue projections
for Theravance Biopharma Inc?

How accurate were the past Revenue estimates
for Theravance Biopharma Inc?

What are the Net Income projections
for Theravance Biopharma Inc?

How accurate were the past Net Income estimates
for Theravance Biopharma Inc?

What are the EPS projections
for Theravance Biopharma Inc?

How accurate were the past EPS estimates
for Theravance Biopharma Inc?

What are the EBIT projections
for Theravance Biopharma Inc?

How accurate were the past EBIT estimates
for Theravance Biopharma Inc?

Compare the revenue forecasts
for Theravance Biopharma Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Theravance Biopharma Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Theravance Biopharma Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Theravance Biopharma Inc compared to its peers.

Compare the P/E ratios
of Theravance Biopharma Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Theravance Biopharma Inc with its peers.

Analyze the financial leverage
of Theravance Biopharma Inc compared to its main competitors.

Show all profitability ratios
for Theravance Biopharma Inc.

Provide ROE
for Theravance Biopharma Inc.

Provide ROA
for Theravance Biopharma Inc.

Provide ROIC
for Theravance Biopharma Inc.

Provide ROCE
for Theravance Biopharma Inc.

Provide Gross Margin
for Theravance Biopharma Inc.

Provide Operating Margin
for Theravance Biopharma Inc.

Provide Net Margin
for Theravance Biopharma Inc.

Provide FCF Margin
for Theravance Biopharma Inc.

Show all solvency ratios
for Theravance Biopharma Inc.

Provide D/E Ratio
for Theravance Biopharma Inc.

Provide D/A Ratio
for Theravance Biopharma Inc.

Provide Interest Coverage Ratio
for Theravance Biopharma Inc.

Provide Altman Z-Score Ratio
for Theravance Biopharma Inc.

Provide Quick Ratio
for Theravance Biopharma Inc.

Provide Current Ratio
for Theravance Biopharma Inc.

Provide Cash Ratio
for Theravance Biopharma Inc.

What is the historical Revenue growth
over the last 5 years for Theravance Biopharma Inc?

What is the historical Net Income growth
over the last 5 years for Theravance Biopharma Inc?

What is the current Free Cash Flow
of Theravance Biopharma Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Theravance Biopharma Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Theravance Biopharma Inc

Current Assets 116.5m
Cash & Short-Term Investments 91.4m
Receivables 16.8m
Other Current Assets 8.3m
Non-Current Assets 239.6m
PP&E 37.1m
Other Non-Current Assets 202.5m
Current Liabilities 23.4m
Accounts Payable 1.5m
Accrued Liabilities 15.5m
Other Current Liabilities 6.5m
Non-Current Liabilities 147m
Long-Term Debt 29.7m
Other Non-Current Liabilities 117.3m
Efficiency

Earnings Waterfall
Theravance Biopharma Inc

Revenue
63.2m USD
Operating Expenses
-102.7m USD
Operating Income
-39.5m USD
Other Expenses
-9.9m USD
Net Income
-49.4m USD

Free Cash Flow Analysis
Theravance Biopharma Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

TBPH Profitability Score
Profitability Due Diligence

Theravance Biopharma Inc's profitability score is 42/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Negative Net Income
ROIC is Increasing
Exceptional Revenue Growth Forecast
42/100
Profitability
Score

Theravance Biopharma Inc's profitability score is 42/100. The higher the profitability score, the more profitable the company is.

TBPH Solvency Score
Solvency Due Diligence

Theravance Biopharma Inc's solvency score is 60/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Negative Net Debt
Long-Term Solvency
60/100
Solvency
Score

Theravance Biopharma Inc's solvency score is 60/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

TBPH Price Targets Summary
Theravance Biopharma Inc

Wall Street analysts forecast TBPH stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for TBPH is 13.464 USD with a low forecast of 9.09 USD and a high forecast of 22.05 USD.

Lowest
Price Target
9.09 USD
8% Downside
Average
Price Target
13.464 USD
36% Upside
Highest
Price Target
22.05 USD
123% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for TBPH?

Click here to dive deeper.

Dividends

Theravance Biopharma Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for TBPH is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

TBPH Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

See Also

Discover More
What is the Intrinsic Value of one TBPH stock?

The intrinsic value of one TBPH stock under the Base Case scenario is 7.174 USD.

Is TBPH stock undervalued or overvalued?

Compared to the current market price of 9.875 USD, Theravance Biopharma Inc is Overvalued by 27%.

Back to Top